Our data provide further evidence of nusinersen safety and efficacy in adult SMA2 and SMA3, with the latter appearing to be cumulative over time. In patients with extremely advanced disease, effects on residual motor function are less clear.
No takes yet. Share an insight, caveat, or question.
Maggi et al. (2020) studied this question.